Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Electronic health record and messaging system; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility, Recurrent Miscarriage
Interventions: Influenza Vaccine, Sterile Saline; Biological · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza, Human, Transplantation Infection
Interventions: influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose; Biological
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Influenza A
Interventions: MHAA4549A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 38
States / cities: Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more

Conditions: Influenza Virus
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine; Biological
Lead sponsor: Armed Forces Research Institute of Medical Sciences, Thailand; Government
Eligibility: 18 Years to 49 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 0
States / cities: Not listed

Conditions: Influenza
Interventions: Text Message, Written reminder; Other
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 9 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: VIS410 low dose, VIS410 high dose, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Huntsville, Alabama • Coral Gables, Florida • Homestead, Florida + 7 more

Conditions: Influenza, Human
Interventions: D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more

Conditions: Herpes Zoster
Interventions: Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania

Conditions: Avian Influenza, Influenza Immunisation
Interventions: Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Viral Pneumonia
Interventions: SNG001, Placebo; Drug
Lead sponsor: Synairgen Research Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Influenza, Human
Interventions: ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more

Conditions: Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions: Fluzone High Dose Vaccine, Standard of care/Placebo; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza
Interventions: Existing Influenza Vaccination Practices, Standardized inpatient influenza vaccination program; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 99 Years
Enrollment: 22,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: COVID-19, Coronavirus Disease 2019, Influenza
Interventions: COVID-19 Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: H5N1 Influenza
Interventions: Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Adult Stem Cell Hematopoetic Transplant
Interventions: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine; Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza
Interventions: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 10 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Torrance, California • Baltimore, Maryland • St Louis, Missouri

Conditions: Influenza, Infections, Pneumococcal
Interventions: Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Influenza
Interventions: Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 6
States / cities: Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more

Search by objective public record fields.

Electronic Health Records for Health Promotion

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

Influenza Vaccine in Lung Transplant Patients - Antibody

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

H5N1 With or Without Topical Aldara in Healthy Adults

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

H1N1 Vaccine in Pregnant Women

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults